Ductal Carcinoma in Situ Clinical Trial
Official title:
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion: a Randomized Phase II Biomarker Trial in Subjects at Increased Risk
Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer. The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases circulating levels of SHBG more than lifestyle intervention (LI) with or without intermittent caloric restriction (ICR) after 6 months in women at increased risk of breast cancer (i.e., healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or with > 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models or with a recently resected intraepithelial neoplasia of the breast (IEN). The secondary aims are: - to verify whether ICR significantly modulates primary and secondary endpoints such as Homeostasis Model Assessment (HOMA) index, immune and inflammatory markers, lipid profile, Adiponectin/Leptin (A/L) ratio, quality of life (QoL), Body mass index (BMI), fat body composition, safety and toxicity; - to verify whether LDT significantly modulates secondary endpoints, such as HOMA-index, immune and inflammatory markers, lipid profile, A/L ratio, QoL, BMI, fat body composition, safety and toxicity; - to investigate differences in microbiome composition by arms and the effect of changes in microbiome on QoL taking into account circulating biomarkers, cytokines, immune modulators, and inflammatory proteins in serum; - to investigate MD (Mammographic Breast Density) changes by LDT vs. LI, with or without ICR. This aim will be performed in a subgroup of participants (not all the participants will undergo mammography due to younger age).
Italian, multicenter, phase II, biomarker trial. A total of 200 women aged 18-70 years will be randomly assigned (1:1:1:1) to one of the four intervention arms Arm 1: Low dose Tamoxifen (LDT) i.e. 10 mg every other day; Arm 2: Low dose Tamoxifen (LDT) + Intermittent Caloric Restriction (ICR); Arm 3: Lifestyle intervention (LI) using a step counter; Arm 4: Lifestyle intervention (LI) using a step counter + Intermittent Caloric Restriction (ICR). Participants will be stratified by center and by disease status (high risk vs. previous IEN) and intervention will last six months for all arms. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02889458 -
Hong Kong Breast Cancer Study
|
||
Completed |
NCT00757302 -
Intraoperative Gamma Camera for Breast Cancer Surgery
|
Phase 3 | |
Active, not recruiting |
NCT03216421 -
Intraoperative Radiation Therapy (IORT) in DCIS
|
N/A | |
Completed |
NCT03775213 -
Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)
|
N/A | |
Active, not recruiting |
NCT00605982 -
Breast MRI as a Preoperative Tool for DCIS
|
N/A | |
Enrolling by invitation |
NCT04365114 -
Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening
|
||
Completed |
NCT04248179 -
The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.
|
Phase 4 | |
Withdrawn |
NCT05032079 -
Subzero and Scorpion Trial
|
N/A | |
Recruiting |
NCT05218044 -
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
|
N/A | |
Active, not recruiting |
NCT01644669 -
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®
|
N/A | |
Recruiting |
NCT06133647 -
Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System
|
||
Completed |
NCT01815476 -
The Prone Breast Radiation Therapy Trial
|
N/A | |
Terminated |
NCT02137252 -
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
|
Phase 2 | |
Terminated |
NCT01060345 -
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
|
Phase 2 | |
Recruiting |
NCT00669747 -
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
|
Phase 2 | |
Completed |
NCT00742222 -
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
|
Phase 4 | |
Active, not recruiting |
NCT02909426 -
The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness
|
||
Recruiting |
NCT02928978 -
Ruxolitinib for Premalignant Breast Disease
|
Phase 2 | |
Completed |
NCT03375892 -
The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure
|
N/A | |
Withdrawn |
NCT03437915 -
BrUOG 351: PRE-OPERATIVE APBI USING NIBB
|
N/A |